It is particularly helpful in improving a healthy brain, maintaining body function, treating nutritional deficiencies, and can be used in lessening the symptoms of neuropathy
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Updated February 21, 2018
The peptides activity does not require a delivery vehicle and is preserved across oral, intraperitoneal, and topical administration routes 2
Every recommendation starts with a comprehensive consultation and is guided by thoughtful medical evaluation and ongoing monitoring